Vital Biopharmaceutical Insights and Analytics

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Featured Report
Osteoporosis: Prolia Fails to Meet Physicians’ Expectations but Retains Blockbuster Potential

A drug’s effect on reduction of new hip fractures is the attribute that most influences U.S. and European surveyed primary care physicians’ (PCPs’) prescribing decisions in osteoporosis. ...Learn More

Featured Webinar
Will the Lack of Efficacious Therapies Open the Door for a New Clinical Gold Standard in Obesity Treatment?

March 17, 2010...Learn More

View Webinar schedule and archive

Search Reports

Filter results:

TOP TEN REPORTS

See which reports have been searched on the most.

In the Spotlight

	Matthew J. Winton, Ph.D. March 18, 2010 10 a.m. ET, 4 p.m. CET
In this presentation, Dr. Winton will discuss the impact of Dimebon’s clinical trial failure on the Alzheimer’s disease drug market… Learn more

Latest Press Releases [ view all ]

March 10, 2010

An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists ...Read More
March 10, 2010

Limited Healthcare Infrastructure and Weak Intellectual Property Protection Are Among the Challenges Pharma Faces With Emerging Market Expansion ...Read More
March 8, 2010

Roche/Genentech/Chugai’s Herceptin As An Add-On to Standard Chemotherapy Will Become Decision Resources’ Clinical Gold Standard in 2013 for the Treatment of Gastric Cancer ...Read More

Recent Reports [ view all ]

Hypertension (Event Driven)

Last Updated 9 March 2010
Hypertension is a chronic disease requiring treatment with blood-pressure-lowering... Read More
Schizophrenia: Emerging Atypical Depot Formulations Must Meet Psychiatrists’ High Expectations to Be Successful in a Generically Threatened Market

The late-stage pipeline of emerging therapies for the treatment of schizophrenia continues to be dominated by atypical... Read More
Strategic Overview of Pricing and Reimbursement in the BRIC Markets

A country whose pharma market is predicted to grow at 21.8% annually merits the attention of the pharma industry. That... Read More